Damora Therapeutics (DMRA) Common Equity (2019 - 2026)
Damora Therapeutics (DMRA) posted Common Equity of $511.6 million for Q1 2026, up 112.83% on a QoQ basis from $240.4 million in Q4 2025, and up 3631.88% year-over-year from $13.7 million in Q1 2025.
Damora Therapeutics (DMRA) Common Equity (2019 - 2026) Analysis & Trends
Damora Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $511.6 million for Q1 2026.
- Quarterly Common Equity rose 3631.88% year-over-year to $511.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $511.6 million (up 3631.88% YoY) and the FY2025 annual result came in at $240.4 million, up 1418.41% from the prior year.
- Common Equity was $511.6 million for Q1 2026 at Damora Therapeutics, up from $240.4 million in the prior quarter.
- Across five years, Common Equity topped out at $511.6 million in Q1 2026 and bottomed at $8.0 million in Q3 2025.
- A 5-year average of $79.9 million and a median of $37.4 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity plunged 61.75% — and 2026, when it surged 3631.88%.
- Damora Therapeutics' Common Equity stood at $61.8 million in 2022, then sank by 47.64% to $32.3 million in 2023, then slumped by 51.03% to $15.8 million in 2024, then soared by 1418.41% to $240.4 million in 2025, then soared by 112.83% to $511.6 million in 2026.
- Business Quant data shows DMRA's Common Equity at $511.6 million in Q1 2026, $240.4 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 511.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 511.60 Mn |
| Dec 31, 2025 | 240.38 Mn |
| Sep 30, 2025 | 8.01 Mn |
| Jun 30, 2025 | 10.95 Mn |
| Mar 31, 2025 | 13.71 Mn |
| Dec 31, 2024 | 15.83 Mn |
| Sep 30, 2024 | 20.94 Mn |
| Jun 30, 2024 | 23.59 Mn |
| Mar 31, 2024 | 28.16 Mn |
| Dec 31, 2023 | 32.33 Mn |
| Sep 30, 2023 | 37.38 Mn |
| Jun 30, 2023 | 43.70 Mn |
| Mar 31, 2023 | 50.33 Mn |
| Dec 31, 2022 | 61.75 Mn |
| Sep 30, 2022 | 72.73 Mn |
| Jun 30, 2022 | 85.07 Mn |
| Mar 31, 2022 | 101.31 Mn |
| Dec 31, 2021 | 117.22 Mn |
| Sep 30, 2021 | 129.62 Mn |
| Jun 30, 2021 | 141.43 Mn |